Attana Application Note: Early detection of clinical failure

Document -

Attana Application Note: Early detection of clinical failure

The objective of this application note was to evaluate newly developed therapeutic antibodies in a biologically relevant context (cells) in order to detect failing candidates at an earlier stage. Among other things, it was found that real-time screening of drug candidates in a synthetic and in a cellular context together provides highly informative and biologically relevant data.
  • License: Media Use
    The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
  • File format: .pdf
Download

Topics

  • Medical research

Categories

  • biosensor
  • attana cell 200
  • cells

Related content

Biosensor- Attana Cell 200, label free, real time kinetics on cells

Revolutionary Swedish invention can potentially improve drug development! Attana AB introduces the Attana Cell 200 – the first system to permit real-time kinetic analysis of molecular interactions directly on cell surfaces, bringing drug development a step closer to the body.

Attana AB launches new software suite

Attana is proud to announce the release of Attaché 2.0, a powerful new software suite developed in collaboration with Ridgeview Instruments AB.

Attana's core business!

View article in Innovations in Pharmaceutical Technology (IPT), a brief overview of Attana's core business. http://www.iptonline.com/viewinn.asp?cat=2&article=285

Attana amongst Sweden's hottest tech companies

Ny Teknik, Sweden’s leading technology and IT newspaper together with Affärsvärlden, Sweden’s largest and most respected business magazine, have selected Attana as one of the hottest tech companies in Sweden.

Attana Launches New Reagents

Attana today announced the launch of a series of four commercial reagents and kits to address customers' needs for high usability and quality research.

Maximising Drug Discovery Research- Interview with Attana CEO, Teodor Aastrup

Attana is one of the sponsor companies at the upcoming marcus evans Discovery Summit 2011 in Cannes, France, 21-23 March. Prior to the event marcus evans and Aastrup discuss in this interview the role biologics can play in speeding up drug discovery and subsequent stages.

PEGS 2011 with Attana!

We are pleased to have met so many like minded members of industry during the Protein Engineering Summit 2011 in Boston last week. If you were there but didn't get the chance to taste our exquisite espresso you are always welcome to stop by our booth during our upcoming events!

Biotech companies - Ways to work more efficiently

Ernst & Young recently released their 24th annual report Beyond borders: global biotechnology report 2010, presenting, among other things, five guiding principles for biotech companies working in the new economy where funding is scarce and customers careful: